Pulmonary hypertension (PHT) is a common complication for patients with β thalassemia intermediate (TI), especially splenectomized patients. However, the frequency and risk factors of PHT in patients with hemoglobin H (HbH) disease is unknown. The purpose of this study was to identify the prevalence of PHT risk manifested as tricuspid regurgitant jet velocity (TRV) ≥2.5 m/s in patients with HbH disease and its correlation with splenectomy. One hundred and ninety-eight patients with HbH disease who visited the 303rd Hospital of the People's Liberation Army (Nanning, China) were investigated. Thirteen subjects (6.5%) were diagnosed as having a risk of PHT. Regression analyses showed that the prevalence of PHT risk was correlated only with age (r = 0.195, p = 0.006) and not with splenectomy. The risk of PHT in patients older than 35 years was 5.7 times (range 1.8-18.6) greater than that for patients younger than 35 years. For splenectomized patients compared to those with HbH disease, patients with TI had a higher frequency of PHT risk, higher nucleated red blood cell counts (46.03 ± 41.11 × 109/l vs. 0.18 ± 1.19 × 109/l, p < 0.001) and a higher platelet counts (837.6 ± 178.9 × 109/l vs. 506.7 ± 146.2 × 109/l, p < 0.001). PHT risk is low in patients with HbH disease and does not correlate with splenectomy. Patients older than 35 years should be monitored regularly.

1.
Weatherall DJ: Keynote address: the challenge of thalassemia for the developing countries. Ann NY Acad Sci 2005;1054:11-17.
2.
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD: Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-1892.
3.
Barnett CF, Hsue PY, Machado RF: Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection. JAMA 2008;299:324-331.
4.
Farmakis D, Aessopos A: Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked. Circulation 2011;123:1227-1232.
5.
Singer ST, Kuypers FA, Styles L, Vichinsky EP, Foote D, Rosenfeld H: Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006;81:670-675.
6.
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M, Cesaretti C, Cappellini MD: Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010;8:2152-2158.
7.
Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT: Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011;96:1605-1612.
8.
Morris CR, Gladwin MT, Kato GJ: Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med 2008;8:620-632.
9.
Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder WC, Schechter AN, Rodgers GP, Castro O, Ognibene FP: Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004;350:886-895.
10.
Tan JA, Lee PC, Wee YC, Tan KL, Mahali NF, George E, Chua KH: High prevalence of alpha- and beta-thalassemia in the Kadazandusuns in East Malaysia: challenges in providing effective health care for an indigenous group. J Biomed Biotechnol 2010, DOI: 10.1155/2010/706872.
11.
Xiong F, Sun M, Zhang X, Cai R, Zhou Y, Lou J, Zeng L, Sun Q, Xiao Q, Shang X, Wei X, Zhang T, Chen P, Xu X: Molecular epidemiological survey of haemoglobinopathies in the Guangxi Zhuang Autonomous Region of southern China. Clin Genet 2010;8:139-148.
12.
Xu XM, Zhou YQ, Luo GX, Liao C, Zhou M, Chen PY, Lu JP, Jia SQ, Xiao GF, Shen X, Li J, Chen HP, Xia YY, Wen YX, Mo QH, Li WD, Li YY, Zhuo LW, Wang ZQ, Chen YJ, Qin CH, Zhong M: The prevalence and spectrum of alpha and beta thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol 2004;57:517-522.
13.
Chui DH, Fucharoen S, Chan V: Hemoglobin H disease: not necessarily a benign disorder. Blood 2003;101:791-800.
14.
Yin XL, Zhang XH, Zhou TH, Zhang TL, Luo RG, Wang L, Zhou YL, Chen YS, Kong XJ, Liang B, He YY, Peng L, Lu LB, Fang SP, Wu ZK: Hemoglobin H disease in Guangxi province, southern China: clinical review of 357 patients. Acta Haematol 2010;124:86-91.
15.
Yin XL, Wu ZK, He YY, Zhou TH, Zhou YL, Zhang XH: Treatment and complications of thalassemia major in Guangxi, southern China. Pediatr Blood Cancer 2011;57:1174-1178.
16.
Yang XY, Qu Q, Yang TY, Chan WC, Chu JX, Chen Z, Ning AL, Liu FJ, Lin ZX, Zhou YL: Treatment of the thalassemia syndrome with splenectomy. Hemoglobin 1988;12:601-608.
17.
Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W: Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006;92:1467-1472.
18.
Morris CR, Kim HY, Trachtenberg F, Wood J, Quinn CT, Sweeters N, Kwiatkowski JL, Thompson AA, Giardina PJ, Boudreaux J, Olivieri NF, Porter JB, Neufeld EJ, Vichinsky EP: Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 2011;118:3794-3802.
19.
Camaschella C, Cappellini MD: Thalassemia intermedia. Haematologica 1995;80:58-68.
20.
Rigas DA, Koler RD: Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy. Blood 1961;18:1-17.
21.
Hathirat P, Isarangkura P, Numhom S, Opasathien P, Chuansumrit A: Results of the splenectomy in children with thalassemia. J Med Assoc Thai 1989;72(suppl 1):133-138.
22.
Amoozgar H, Farhani N, Karimi M: Early echocardiographic findings in beta-thalassemia intermedia patients using standard and tissue Doppler methods. Pediatr Cardiol 2011;32:154-159.
23.
Karimi M, Musallam KM, Cappellini MD, Daar S, El-Beshlawy A, Belhoul K, Saned MS, Temraz S, Koussa S, Taher AT: Risk factors for pulmonary hypertension in patients with beta thalassemia intermedia. Eur J Intern Med 2011;22:607-610.
24.
Lithanatudom P, Leecharoenkiat A, Wannatung T, Svasti S, Fucharoen S, Smith DR: A mechanism of ineffective erythropoiesis in beta-thalassemia/Hb E disease. Haematologica 2010;95:716-723.
25.
Danise P, Amendola G, Di CR, Cillari E, Gioia M, Di PA, Avino D, Rigano P, Maggio A: Nucleated red blood cells and soluble transferrin receptor in thalassemia syndromes: relationship with global and ineffective erythropoiesis. Clin Chem Lab Med 2009;47:1539-1542.
26.
Aessopos A, Kati M, Farmakis D: Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007;92:658-665.
27.
Amoozgar H, Farhani N, Karimi M: Risk factors for pulmonary hypertension in patients with thalassemia intermedia. Eur J Haematol 2010;85:549-551.
28.
Winichagoon P, Fucharoen S, Wasi P: Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health 1981;12:556-560.
29.
Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P: Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health 1980;11:516-523.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.